Gilead Sciences Inc. (GILD:US)’s board scheduled a 2-for-1 stock split as optimism about the company’s experimental hepatitis C drug pushed shares to record highs.
Stockholders on Jan. 7, will receive an additional share, Gilead said today in a statement. The split will increase the number of outstanding common shares to 1.5 billion, the Foster City, California-based company said. After such an action, a company’s stock usually trades at half as much per share as before the division.
Gilead, the world’s largest maker of HIV medicines, rose less than 1 percent to $74.25 at the close in New York before the split was announced. The company’s shares closed at $76.12 on Nov. 23, the highest level since Gilead first offered stock in 1992, as its experimental drugs to treat hepatitis C have shown to be effective and safe in clinical trials.
To contact the reporter on this story: Ryan Flinn in San Francisco at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com